COL1A2 and colitis: In a pre-clinical study, RXC008 demonstrated anti-fibrotic effects in adoptive T-cell transfer and chronic DSS murine models of colitis, suppressing fibrosis and reducing the expression of fibrotic markers such as COL1A1, COL1A2, and TGFB1.